122 related articles for article (PubMed ID: 9833958)
21. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
[TBL] [Abstract][Full Text] [Related]
22. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.
Catani MV; Corasaniti MT; Navarra M; Nisticò G; Finazzi-Agrò A; Melino G
J Neurochem; 2000 Jun; 74(6):2373-9. PubMed ID: 10820198
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
[TBL] [Abstract][Full Text] [Related]
24. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
[TBL] [Abstract][Full Text] [Related]
25. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
[TBL] [Abstract][Full Text] [Related]
26. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state.
Amzazi S; Ylisastigui L; Bakri Y; Rabehi L; Gattegno L; Parmentier M; Gluckman JC; Benjouad A
Virology; 1998 Dec; 252(1):96-105. PubMed ID: 9875320
[TBL] [Abstract][Full Text] [Related]
28. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
[TBL] [Abstract][Full Text] [Related]
29. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
Guan X; Chaffey PK; Chen H; Feng W; Wei X; Yang LM; Ruan Y; Wang X; Li Y; Barosh KB; Tran AH; Zhu J; Liang W; Zheng YT; Wang X; Tan Z
Biochemistry; 2018 Jan; 57(1):136-148. PubMed ID: 29202246
[TBL] [Abstract][Full Text] [Related]
30. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis.
Mayanja-Kizza H; Wajja A; Wu M; Peters P; Nalugwa G; Mubiru F; Aung H; Vanham G; Hirsch C; Whalen C; Ellner J; Toossi Z
J Infect Dis; 2001 Jun; 183(12):1801-4. PubMed ID: 11372034
[TBL] [Abstract][Full Text] [Related]
31. High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.
Rico CA; Berchiche YA; Horioka M; Peeler JC; Lorenzen E; Tian H; Kazmi MA; Fürstenberg A; Gaertner H; Hartley O; Sakmar TP; Huber T
Biophys J; 2019 Sep; 117(5):903-919. PubMed ID: 31421836
[TBL] [Abstract][Full Text] [Related]
32. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant.
Lim JK; Lu W; Hartley O; DeVico AL
J Leukoc Biol; 2006 Dec; 80(6):1395-404. PubMed ID: 16963625
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors.
Jiang JD; Wilk S; Li J; Zhang H; Bekesi JG
Res Virol; 1997; 148(4):255-66. PubMed ID: 9272576
[TBL] [Abstract][Full Text] [Related]
34. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
[TBL] [Abstract][Full Text] [Related]
35. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
[TBL] [Abstract][Full Text] [Related]
36. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.
Ylisastigui L; Vizzavona J; Drakopoulou E; Paindavoine P; Calvo CF; Parmentier M; Gluckman JC; Vita C; Benjouad A
AIDS; 1998 Jun; 12(9):977-84. PubMed ID: 9662193
[TBL] [Abstract][Full Text] [Related]
37. Enhanced replication of M-tropic HIV-1 strains in Herpesvirus saimiri immortalised T-cells which express CCR5.
Vella C; Zheng NN; Vella G; Atkins C; Bristow RG; Fickenscher H; Daniels RS
J Virol Methods; 1999 Apr; 79(1):51-63. PubMed ID: 10328535
[TBL] [Abstract][Full Text] [Related]
38. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
[TBL] [Abstract][Full Text] [Related]
39. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
